The journal takes the premise that innovative approaches β including gene therapy, cell therapy, and epigenetic modulation β will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases.
With the changing emphasis from genetic to epigenetic understandings of pathology including telomere biology , with the use of gene delivery systems including viral delivery systems , and with the use of cell-based therapies including stem cell therapies , a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21 st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials. Papers must be clear and concise, but detailed data is strongly encouraged.
There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed median values for papers published in : Submission to First Decision: 6. Susan E. OBM Geriatrics ; 6 4 : ; doi This is an open access article distributed under the conditions of the Creative Commons by Attribution License , which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited. As such, this research examined the use of two types of mobile devices, smartphones, and tablets, by older adults i.
